KCT0000312招募中未知
An Open-label, Multi-center Phase II Trial to evaluate the efficacy and Safety of Combination Chemotherapy With DoceTaxel and Gemcitabine
Korean Breast Cancer Society0 个研究点目标入组 99 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 99
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 70(Year)（—）
- 性别
- Female
入选标准
- •1.pathologically proved breast cancer
- •2. no distant metastasis confirmed pathologically or radiologically
- •3. 20-70 years old female
- •4. ECOG performance: 0~2
- •5. No previous anti-cancer treatment
- •6. more than one lesion measurable by chest CT
- •7. Ample bone marrow, liver, kidney function within 2 weeks
- •8. Mentally sound person understanding her rights to ban the clinical trial and protocol/ ICF.
排除标准
- •1. distant metastasis from breast cancer
- •2. HER-2 (+)
- •3. active cancer otherwise breast cancer (except cervix CIS or basal/squamous cell carcinoma which are properly treated)
- •4. Pregnancy, during lactation
- •5. Within 6 months, clinically significant heart problems
- •6. Uncontrollable systemic infection
研究者
相似试验
进行中（未招募）
1 期
Phase 2 study of lenvatinib plus pembrolizumab for advanced melanoma in anti-PD-1/L1-exposed participantsMedDRA version: 20.0 Level: LLT Classification code 10053571 Term: Melanoma System Organ Class: 100000004864Advanced melanomaEUCTR2018-002518-10-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.100
进行中（未招募）
1 期
Phase 2 study of lenvatinib plus pembrolizumab for advanced melanoma in anti-PD-1/L1-exposed participantsAdvanced melanomaEUCTR2018-002518-10-SEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.100
未知
2 期
An Open-label, Multi-center, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects with Advanced Soft Tissue SarcomaSoft Tissue SarcomaJPRN-jRCT2080221635Eisai Co., Ltd.51
进行中（未招募）
不适用
A Phase II, Open-label, multi center Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly SubjectsThe present study is therefore designed to evaluate the immunogenicity, safety and tolerability of two doses of FLUAD-H5N1 vaccine containing A/H5N1/turkey/Turkey/05 administered 3 weeks apart in non-elderly adult and elderly subjects.EUCTR2008-000895-25-HUovartis Vaccines and Diagnostics GmbH & Co. KG334
进行中（未招募）
1 期
A Multicenter, Open-Label, Phase 2 Trial to Evaluate the Safety and Activity of Efgartigimod (ARGX-113) in Adult Patients with Primary Immune Thrombocytopenia - ARGX-113-1804Primary Immune ThrombocytopeniaMedDRA version: 20.1Level: LLTClassification code 10074678Term: Primary immune thrombocytopenic purpuraSystem Organ Class: 100000004851EUCTR2019-000361-21-GBArgenx BVBA15